Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Yuwen Zhou, Yao Xie, Liansha Tang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 102

Showing 1-25 of 102 citing articles:

Long COVID: a clinical update
Trisha Greenhalgh, Manoj Sivan, Alice Perlowski, et al.
The Lancet (2024) Vol. 404, Iss. 10453, pp. 707-724
Closed Access | Times Cited: 97
The Remarkable Evolutionary Plasticity of Coronaviruses by Mutation and Recombination: Insights for the COVID-19 Pandemic and the Future Evolutionary Paths of SARS-CoV-2
Grigoris D. Amoutzias, Marios Nikolaidis, Eleni Tryfonopoulou, et al.
Viruses (2022) Vol. 14, Iss. 1, pp. 78-78
Open Access | Times Cited: 82
Structure-based drug repurposing: Traditional and advanced AI/ML-aided methods
Chinmayee Choudhury, N. Arul Murugan, U. Deva Priyakumar
Drug Discovery Today (2022) Vol. 27, Iss. 7, pp. 1847-1861
Open Access | Times Cited: 80
Therapeutics for COVID-19 and post COVID-19 complications: An update
Debdoot Basu, Vivek P. Chavda, Anita A. Mehta
Current Research in Pharmacology and Drug Discovery (2022) Vol. 3, pp. 100086-100086
Open Access | Times Cited: 69
Advances in the development of therapeutic strategies against COVID-19 and perspectives in the drug design for emerging SARS-CoV-2 variants
Jialing Yin, Chengcheng Li, Chunhong Ye, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 824-837
Open Access | Times Cited: 65
Targeting genomic SARS-CoV-2 RNA with siRNAs allows efficient inhibition of viral replication and spread
Shubhankar Ambike, Cho‐Chin Cheng, Martin Feuerherd, et al.
Nucleic Acids Research (2021) Vol. 50, Iss. 1, pp. 333-349
Open Access | Times Cited: 59
Pathophysiological mechanisms of thrombosis in acute and long COVID-19
Haijiao Jing, Xiaoming Wu, Mengqi Xiang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 53
Immune responses in mildly versus critically ill COVID-19 patients
Hamid Nasrollahi, Atefe Ghamar Talepoor, Zahra Saleh, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 42
CircRNAs: Pivotal modulators of TGF-β signalling in cancer pathogenesis
Asif Ahmad Bhat, Gaurav Gupta, Rajiv Dahiya, et al.
Non-coding RNA Research (2024) Vol. 9, Iss. 2, pp. 277-287
Open Access | Times Cited: 16
Principles for optimization and validation of mRNA lipid nanoparticle vaccines against COVID-19 using 3D bioprinting
Massimiliano Papi, Daniela Pozzi, Valentina Palmieri, et al.
Nano Today (2022) Vol. 43, pp. 101403-101403
Open Access | Times Cited: 37
Biomarkers during COVID-19: Mechanisms of Change and Implications for Patient Outcomes
Cheng‐Han Chen, Sheng-Wen Lin, Ching‐Fen Shen, et al.
Diagnostics (2022) Vol. 12, Iss. 2, pp. 509-509
Open Access | Times Cited: 36
Virus-host interaction networks as new antiviral drug targets for IAV and SARS-CoV-2
Na Chen, Baoge Zhang, Lulu Deng, et al.
Emerging Microbes & Infections (2022) Vol. 11, Iss. 1, pp. 1371-1389
Open Access | Times Cited: 34
Roles of host proteases in the entry of SARS-CoV-2
Alexandria Zabiegala, Yunjeong Kim, Kyeong‐Ok Chang
Animal Diseases (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 19
Allosteric inhibition of SARS-CoV-2 3CL protease by colloidal bismuth subcitrate
Xuan Tao, Lu Zhang, Liubing Du, et al.
Chemical Science (2021) Vol. 12, Iss. 42, pp. 14098-14102
Open Access | Times Cited: 33
Multi-stage structure-based virtual screening approach towards identification of potential SARS-CoV-2 NSP13 helicase inhibitors
Mahmoud A. El Hassab, Wagdy M. Eldehna, Sara T. Al‐Rashood, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2022) Vol. 37, Iss. 1, pp. 563-572
Open Access | Times Cited: 26
Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions
E. Alperay Tarim, Müge Anıl-İnevi, Ilayda Ozkan, et al.
Biomedical Microdevices (2023) Vol. 25, Iss. 2
Open Access | Times Cited: 16
Dual COX-2/15-LOX inhibitors: A new avenue in the prevention of cancer
Ali Aliabadi, Elham Khanniri, Mohammad Mahboubi‐Rabbani, et al.
European Journal of Medicinal Chemistry (2023) Vol. 261, pp. 115866-115866
Closed Access | Times Cited: 14
Discovering novel Cathepsin L inhibitors from natural products using artificial intelligence
Qi Li, Si-Rui Zhou, Hanna Kim, et al.
Computational and Structural Biotechnology Journal (2024) Vol. 23, pp. 2606-2614
Open Access | Times Cited: 5
Regulation of m6A Methylation as a New Therapeutic Option against COVID-19
Carla Zannella, Luca Rinaldi, Giovanni Boccia, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 11, pp. 1135-1135
Open Access | Times Cited: 32
Potential drug discovery for COVID-19 treatment targeting Cathepsin L using a deep learning-based strategy
Weili Yang, Qi Li, Jing Sun, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 2442-2454
Open Access | Times Cited: 21
Ethnomedicinal, Phytochemistry and Antiviral Potential of Turmeric (Curcuma longa)
Bajarang Bal Lal Srivastava, Asha Ripanda, Hossein Miraji
Compounds (2022) Vol. 2, Iss. 3, pp. 200-221
Open Access | Times Cited: 21
Pharmacological approaches to pulmonary fibrosis following COVID-19
Štefan Laššán, Tomáš Tesař, J Tisonová, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 13
The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro
Yue Shen, William Eades, William Liu, et al.
Drug Metabolism and Disposition (2022) Vol. 50, Iss. 9, pp. 1151-1160
Open Access | Times Cited: 17
Comprehensive Fragment Screening of the SARS‐CoV‐2 Proteome Explores Novel Chemical Space for Drug Development
Hannes Berg, Maria A. Wirtz Martin, Nadide Altincekic, et al.
Angewandte Chemie International Edition (2022) Vol. 61, Iss. 46
Open Access | Times Cited: 17
Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors
Nicoletta Brindani, Federico Munafò, Andrea Menichetti, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 80, pp. 117179-117179
Open Access | Times Cited: 11
Page 1 - Next Page

Scroll to top